Europäische Union - Deutsch - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinibmaleat - mittel gegen dermatitis, ausgenommen corticosteroide - hunde - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - oclacitinibum - filmtabletten für hunde - oclacitinibum 3.6 mg ut oclacitinibi maleas, cellulosum microcristallinum, lactosum monohydricum, carboxymethylamylum natricum a, magnesii stearas, Überzug: lactosum monohydricum, hypromellosum, titanii dioxidum, macrogolum 400, pro compresso obducto. - dermatologikum für hunde - synthetika

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - oclacitinibum - filmtabletten für hunde - oclacitinibum 5.4 mg ut oclacitinibi maleas, cellulosum microcristallinum, lactosum monohydricum, carboxymethylamylum natricum a, magnesii stearas, Überzug: lactosum monohydricum, hypromellosum, titanii dioxidum, macrogolum 400, pro compresso obducto. - dermatologikum für hunde - synthetika

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - oclacitinibum - filmtabletten für hunde - oclacitinibum 16 mg ut oclacitinibi maleas, cellulosum microcristallinum, lactosum monohydricum, carboxymethylamylum natricum a, magnesii stearas, Überzug: lactosum monohydricum, hypromellosum, titanii dioxidum, macrogolum 400, pro compresso obducto. - dermatologikum für hunde - synthetika

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - oclacitinibum - kautabletten für hunde - oclacitinibum 3.6 mg ut oclacitinibi maleas, hepar suilli pulverisatum, crospovidonum, carboxymethylamylum natricum a, glyceroli monostearas 40-55, macrogolum 3350, glycerolum, natrii chloridum, xanthani gummi, faex siccata, silica colloidalis anhydrica, magnesii stearas, pro compresso. - dermatologikum für hunde - synthetika

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - oclacitinibum - kautabletten für hunde - oclacitinibum 5.4 mg ut oclacitinibi maleas, hepar suilli pulverisatum, crospovidonum, carboxymethylamylum natricum a, glyceroli monostearas 40-55, macrogolum 3350, glycerolum, natrii chloridum, xanthani gummi, faex siccata, silica colloidalis anhydrica, magnesii stearas, pro compresso. - dermatologikum für hunde - synthetika

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - oclacitinibum - kautabletten für hunde - oclacitinibum 16 mg ut oclacitinibi maleas, hepar suilli pulverisatum, crospovidonum, carboxymethylamylum natricum a, glyceroli monostearas 40-55, macrogolum 3350, glycerolum, natrii chloridum, xanthani gummi, faex siccata, silica colloidalis anhydrica, magnesii stearas, pro compresso. - dermatologikum für hunde - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 und 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - filmtabletten - tofacitinibum 5 mg zu tofacitinibi citras, excipiens pro compresso dunst. - selektives immunsuppressivum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - filmtabletten - tofacitinibum 10 mg zu tofacitinibi citras, color.: e 132, e 133, excipiens pro compresso dunst. - selektives immunsuppressivum - synthetika